New developments in imaging and functional biomarker technology for the assessment and management of cancer patients

Expert Review of Medical Devices

Volumn 6, Issue 4, 2009, Pages 347-351

  Hall, Nathan C ^a   Zhang, Jun ^a   Povoski, Stephen P ^b   Martin Jr , Edward W ^b   Knopp, Michael V ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

CANCER DIAGNOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DEVELOPMENT; EDITORIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SAFETY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIOTECHNOLOGY; DIAGNOSTIC IMAGING; HUMANS; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69949157257     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.21     Document Type: Editorial

References (46)

1. Yang DJ, Kim EE, Inoue T. Targeted molecular imaging in oncology. Ann. Nucl. Med. 20(1), 1-11 (2006).
2. Weissleder R. Molecular imaging in cancer. Science 312(5777), 1168-1171 (2006).
3. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 452(7187), 580-589 (2008).
4. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu. Rev. Med. 57, 99-118 (2006).
5. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin. Cancer Res. 13(12), 3470-3481 (2007).
6. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol. Med. 13(7), 287-297 (2007).
7. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat. Clin. Pract. Oncol. 5(1), 44-54 (2008).
8. Serganova I, Blasberg RG. Multi-modality molecular imaging of tumors. Hematol. Oncol. Clin. North Am. 20(6), 1215-1248 (2006).
9. Papathanassiou D, Liehn JC. The growing development of multimodality imaging in oncology. Crit. Rev. Oncol. Hematol. 68(1), 60-65 (2008).
10. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7(7), 591-607 (2008).
11. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging 5(Spec. No. A), S16-S26 (2005).
12. Niu G, Chen X. Has molecular and cellular imaging enhanced drug discovery and drug development? Drugs R. D. 9(6), 351-368 (2008).
13. Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjug. Chem. 20(4), 631-643 (2009).
14. Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imaging in small animal research. Cell. Oncol. 28(4), 127-139 (2006).
15. Lyons SK. Advances in imaging mouse tumour models in vivo. J. Pathol. 205(2), 194-205 (2005).
16. Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res. 10(Suppl. 1), S3 (2008).
17. Imam SK. Molecular nuclear imaging: the radiopharmaceuticals (review). Cancer Biother. Radiopharm. 20(2), 163-172 (2005).
18. Hoffman JM, Gambhir SS, Kelloff GJ. Regulatory and reimbursement challenges for molecular imaging. Radiology 245(3), 645-660 (2007).
19. Coleman RE. Single photon emission computed tomography and positron emission tomography in cancer imaging. Cancer 67(4 Suppl.), 1261-1270 (1991).
20. Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin. Transl. Oncol. 9(8), 494-505 (2007).
21. Townsend DW. Positron emission tomography/computed tomography. Semin. Nucl. Med. 38(3), 152-166 (2008).
22. Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin. Radiol. 63(3), 241-251 (2008).
23. Tagliabue L, Schillaci O. SPECT/CT in oncology: the fusion of two imaging modalities is a new standard of care. Q. J. Nucl. Med. Mol. Imaging 51(4), 285-289 (2007).
24. Maurer AH. Combined imaging modalities: PET/CT and SPECT/CT. Health Phys. 95(5), 571-576 (2008).
25. Hicks RJ, Lau EW. PET/MRI: a different spin from under the rim. Eur. J. Nucl. Med. Mol. Imaging 36(Suppl. 1), S10-S14 (2009).
26. Morikawa M, Demura Y, Ishizaki T et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. J. Nucl. Med. 50(1), 81-87 (2009).
27. Seiboth L, Van Nostrand D, Wartofsky L et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid 18(2), 103-111 (2008).
28. Moy L, Ponzo F, Noz ME et al. Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J. Nucl. Med. 48(4), 528-537 (2007).
29. Ruf J, Lopez Hanninen E, Bohmig M et al. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology 6(6), 512-519 (2006).
30. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur. Radiol. 18(6), 1077-1086 (2008).
31. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur. J. Nucl. Med. Mol. Imaging 36(Suppl. 1), S113-S120 (2009).
32. Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br. J. Cancer 99(6), 911-922 (2008).
33. Judenhofer MS, Wehrl HF, Newport DF et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14(4), 459-465 (2008).
34. Choyke PL, Knopp MV, Libutti SK. Special techniques for imaging blood flow to tumors. Cancer J. 8(2), 109-118 (2002).
35. Knopp MV, von Tengg-Kobligk H, Choyke PL. Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring. Mol. Cancer Ther. 2(4), 419-426 (2003).
36. Nanni C, Rubello D, Khan S, Al-Nahhas A, Fanti S. Role of small animal PET in stimulating the development of new radiopharmaceuticals in oncology. Nucl. Med. Commun. 28(6), 427-429 (2007).
37. Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/ CT: important tools for preclinical investigation. J. Nucl. Med. 49(10), 1651-1663 (2008).
38. Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr. Top. Med. Chem. 5(11), 1053-1075 (2005).
39. Acton PD, Kung HF. Small animal imaging with high resolution single photon emission tomography. Nucl. Med. Biol. 30(8), 889-895 (2003).
40. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000).
41. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur. J. Cancer 42(8), 1031-1039 (2006).
42. Hillman BJ, Gatsonis C. The American College of Radiology Imaging Network - clinical trials of diagnostic imaging and image-guided treatment. Semin. Oncol. 35(5), 460-469 (2008).
43. Sikora K. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv. Cancer Res. 96, 345-369 (2007).
44. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 244(1), 39-47 (2007).
45. Lawrence YR, Werner-Wasik M, Dicker AP. Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncol. 4(5), 689-704 (2008).
46. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW. Bringing advanced medical imaging into the operative arena could revolutionize the surgical care of cancer patients. Expert Rev. Med. Devices 5(6), 663-667 (2008).